Oral ONC201 in Adult Recurrent Glioblastoma

Trial Profile

Oral ONC201 in Adult Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs ONC 201 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Oncoceutics
  • Most Recent Events

    • 13 Nov 2017 Results from predictive and pharmacodynamic biomarker analyses presented in an Oncoceutics media release.
    • 13 Nov 2017 According to an Oncoceutics media release, data from predictive and pharmacodynamic biomarker analyses will be presented at the 22nd Annual Scientific Meeting and Education Day of the Society of Neuro-Oncology.
    • 29 Mar 2017 According to an Oncoceutics media release, results from the first cohort of patients will be reported in scientific forums throughout this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top